KR870007201A - 헵타노일- glu-asp-ala-아미노산 면역 자극물질 - Google Patents

헵타노일- glu-asp-ala-아미노산 면역 자극물질 Download PDF

Info

Publication number
KR870007201A
KR870007201A KR870000489A KR870000489A KR870007201A KR 870007201 A KR870007201 A KR 870007201A KR 870000489 A KR870000489 A KR 870000489A KR 870000489 A KR870000489 A KR 870000489A KR 870007201 A KR870007201 A KR 870007201A
Authority
KR
South Korea
Prior art keywords
hydrogen
compound
formula
pharmaceutically acceptable
tert
Prior art date
Application number
KR870000489A
Other languages
English (en)
Other versions
KR900003515B1 (ko
Inventor
미챌 브라이트 진
Original Assignee
윌리암 데이비스 훈
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 윌리암 데이비스 훈, 화이자 인코포레이티드 filed Critical 윌리암 데이비스 훈
Publication of KR870007201A publication Critical patent/KR870007201A/ko
Application granted granted Critical
Publication of KR900003515B1 publication Critical patent/KR900003515B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

내용 없음

Description

헵타노일-GLU-ASP-ALA-아미노산 면역 자극물질
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (15)

  1. 일반식(Ⅰ)의 화합물 및 Y,Z,R1및 R2중의 적어도 하나가 수소인 일반식(Ⅰ) 화합물의 약제학적으로 허용되는 염.
    상기 식에서
    R1은 수소 또는 벤질이고,
    R2는 수소 또는 메틸이며,
    R3는
    Z는 수소 또는 카보벤지질옥이며,
    Y는 수소 또는 3급-부톡시카보닐이다.
  2. 제1항에 있어서, R3가인 화합물.
  3. 제2항에 있어서, Y 및 R1이 각기 수소인 화합물.
  4. 제3항에 있어서, R2가 수소인 화합물.
  5. 제1항에 있어서, R3가인 화합물.
  6. 제5항에 있어서, R1및 Z가 각기 수소인 화합물.
  7. 제5항에 있어서, R2가 수소인 화합물.
  8. 일반식(Ⅱ)의 화합물
    상기 식에서,
    X는 수소 또는 3급-부틸이다.
  9. 제8항에 있어서, X가 수소인 화합물.
  10. 제8항에 있어서, X가 3급-부틸인 화합물.
  11. 일반식(Ⅲ)의 화합물.
    상기 식에서
    Z는 수소 또는 벤질옥시카보닐이다.
  12. 제11항에 있어서, Z가 수소인 화합물.
  13. 일반식(Ⅰ)의 화합물을 탈차단시킴을 특징으로 하여, 일반식(Ⅰ-A)의 화합물을 제조하는 방법.
    상기식에서
    R1는 수소 또는 벤질이며,
    R2는 수소 또는 메틸이고,
    Y는 수소 또는 3급-부틸옥시카보닐이며,
    Z는 수소 또는 카보벤질옥시이고,
    단, R1, R2, Y 및 Z 중의 적어도 하나는 수소가 아니다.
  14. R1, R2, Y 및 Z가 각기 수소인 제1항의 화합물 또는 이의 약제학적으로 허용되는 염의 항감염제로서의 용도.
  15. R1, R2, Y 및 Z가 각기 수소인 제1항의 화합물 또는 이의 약제학적으로 허용되는 염의 면역자극 유효량과 약제학적으로 허용되는 담체로 이루어진 약제학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870000489A 1986-01-23 1987-01-22 헵타노일-glu-asp-ala-아미노산 면역자극물질 KR900003515B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US1986/000126 WO1987004440A1 (en) 1986-01-23 1986-01-23 Heptanoyl-glu-asp-ala-amino acid immunostimulants
USPCT/US86/00126 1986-01-23
US126 1986-01-23

Publications (2)

Publication Number Publication Date
KR870007201A true KR870007201A (ko) 1987-08-17
KR900003515B1 KR900003515B1 (ko) 1990-05-21

Family

ID=22195344

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870000489A KR900003515B1 (ko) 1986-01-23 1987-01-22 헵타노일-glu-asp-ala-아미노산 면역자극물질

Country Status (19)

Country Link
US (1) US4851388A (ko)
EP (1) EP0231087B1 (ko)
JP (3) JPH0647599B2 (ko)
KR (1) KR900003515B1 (ko)
AT (1) ATE74138T1 (ko)
AU (1) AU568996B2 (ko)
CA (1) CA1295085C (ko)
DE (1) DE3777665D1 (ko)
DK (1) DK34087A (ko)
ES (1) ES2032437T3 (ko)
FI (1) FI874123A (ko)
GR (1) GR3004346T3 (ko)
HU (1) HU201094B (ko)
IE (1) IE59174B1 (ko)
IL (1) IL81337A (ko)
NZ (1) NZ219012A (ko)
PT (1) PT84157B (ko)
WO (1) WO1987004440A1 (ko)
ZA (1) ZA87466B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
US5599903A (en) * 1992-04-03 1997-02-04 Terrapin Technologies, Inc. Glutathione analogs and paralog panels comprising glutathione mimics
DE3930739A1 (de) * 1989-09-14 1991-03-28 Sandoz Ag Neue acylpeptide, verfahren zu ihrer herstellung und ihre verwendung
IT1237474B (it) * 1989-10-05 1993-06-07 Polifarma Spa Composti tripeptidici e loro uso farmaceutico come immuno-modulatori
US5444042A (en) * 1990-12-28 1995-08-22 Cortex Pharmaceuticals Method of treatment of neurodegeneration with calpain inhibitors
US5786336A (en) * 1991-04-29 1998-07-28 Terrapin Technologies, Inc. Target-selective protocols based on mimics
US5767086A (en) * 1992-04-03 1998-06-16 Terrapin Technologies, Inc. Bone marrow stimulation by certain glutathione analogs
US5955432A (en) * 1992-04-03 1999-09-21 Terrapin Technologies, Inc. Metabolic effects of certain glutathione analogs
US5908919A (en) * 1993-10-01 1999-06-01 Terrapin Technologies Urethane mediated, GST specific molecular release systems

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4354966A (en) * 1978-11-14 1982-10-19 Fujisawa Pharmaceutical Co., Ltd. Peptides, process for preparation thereof and use thereof
US4411925A (en) * 1980-01-21 1983-10-25 Pfizer Inc. Branched amides of L-aspartyl-d-amino acid dipeptides
US4394308A (en) * 1980-05-27 1983-07-19 Chimicasa Gmbh Method of producing α-L-aspartyl-L-phenylalanine methylesters
GR81332B (ko) * 1980-12-01 1984-12-11 Fujisawa Pharmaceutical Co
US4399066A (en) * 1981-01-29 1983-08-16 Fujisawa Pharmaceutical Co., Ltd. Novel peptide, process for preparation thereof and use thereof
US4619915A (en) * 1984-10-19 1986-10-28 Pfizer Inc. Peptide-substituted heterocyclic immunostimulants
JPS61148198A (ja) * 1984-12-22 1986-07-05 Ajinomoto Co Inc 新規トリペプチド化合物および甘味剤
CA1295784C (en) * 1985-11-25 1992-02-11 James Patrick Rizzi Peptide immunostimulants

Also Published As

Publication number Publication date
ATE74138T1 (de) 1992-04-15
ES2032437T3 (es) 1993-02-16
WO1987004440A1 (en) 1987-07-30
AU6790987A (en) 1987-07-30
JPH06122697A (ja) 1994-05-06
NZ219012A (en) 1988-11-29
PT84157B (pt) 1989-07-31
IL81337A0 (en) 1987-08-31
ZA87466B (en) 1988-07-22
FI874123A0 (fi) 1987-09-22
JPH0647599B2 (ja) 1994-06-22
HUT46043A (en) 1988-09-28
EP0231087A2 (en) 1987-08-05
HU201094B (en) 1990-09-28
IE870169L (en) 1987-07-23
DE3777665D1 (de) 1992-04-30
IE59174B1 (en) 1994-01-26
PT84157A (en) 1987-02-01
IL81337A (en) 1991-06-30
JPS62178600A (ja) 1987-08-05
US4851388A (en) 1989-07-25
AU568996B2 (en) 1988-01-14
FI874123A (fi) 1987-09-22
DK34087D0 (da) 1987-01-22
EP0231087B1 (en) 1992-03-25
GR3004346T3 (ko) 1993-03-31
JPH075630B2 (ja) 1995-01-25
DK34087A (da) 1987-10-16
JPH0747600B2 (ja) 1995-05-24
KR900003515B1 (ko) 1990-05-21
EP0231087A3 (en) 1989-11-23
JPH06122698A (ja) 1994-05-06
CA1295085C (en) 1992-01-28

Similar Documents

Publication Publication Date Title
DE3365772D1 (en) 1,4-dihydropyridines, process for their preparation and their application as pharmaceutical preparations
AU579387B2 (en) New tetrapyrrole therapeutic agents
DE3363244D1 (en) Compounds, process for their preparation and their use as pharmaceutical preparations
AU6954887A (en) Oligopeptidyl nitrile derivatives, agents containing them, a process for their preparation, and their use
KR870007201A (ko) 헵타노일- glu-asp-ala-아미노산 면역 자극물질
DE3570437D1 (en) 1-hydroxy-1,1-diphosphonic-acid derivatives, process for their preparation and pharmaceutical preparations, especially for the treatment of bone tumours
DE3065435D1 (en) Thiazole derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
DK171487A (da) Spergualinderivater, fremgangsmaade til deres fremstilling og deres anvendelse som laegemidler
KR900001715A (ko) Bu-3608 유도체
FR2597097B1 (fr) Derives de benzothiazepine-1, 5, leur preparation et leur application en therapeutique
KR890003755A (ko) 7- (2- 메틸- 4- 아미노피롤리디닐)나프티리딘 및 퀴놀린 화합물
EP0061234A3 (en) Cephalosporin derivatives, process for their preparation and pharmaceutical preparations containing them
ATE133686T1 (de) Peptid-antibiotika
DE3371628D1 (en) 1-aroyl-5-oxo-2-pyrrolidinepropanoic acids and related esters
ATE46347T1 (de) Immunostimulierende peptide.
WO1987004435A3 (en) Xanthine compounds
ATE10934T1 (de) Peptid, verfahren zu dessen herstellung und dessen verwendung.
KR920002139A (ko) 뇌혈관 수축 치료제
GB2022092A (en) Cephalosporin Analogues and Processes for the Preparation Thereof

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19950317

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee